Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 8.3- Skyepharma PLC

11 Jan 2006 12:23

HBM BioVentures (Cayman) Ltd11 January 2006 FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of person dealing (Note 1) HBM BioVentures (Cayman) Ltd Company dealt in SkyePharma Plc Class of relevant security Ordinary Sharesto which the dealings being disclosed relate (Note 2) Date of dealing 10 January 2006 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) Long Short Number (%) Number (%) (1) Relevant securities 64,400,450 (8.54%) (2) Derivatives (other than options) NA (3) Options and agreements to purchase/sell NA Total 64,400,450 (8.54%) (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5) PURCHASE 620,000 0.499369 (b) Derivatives transactions (other than options) Product name, Long/short Number of securities Price per unit e.g. CFD (Note 6) (Note 7) (Note 5) (c) Options transactions in respect of existing securities(i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Option moneyname, selling, securities price American, date paid/e.g. purchasing, to which European received call varying etc. the option etc. per unit option relates (Note 5) (Note 7) (ii) Exercising Product name, e.g. Number of securities Exercise price per unit call option (Note 5) (d) Other dealings (including new securities)(Note 4) Nature of transaction Details Price per unit (Note 8) (if applicable) (Note 5) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure 10 January 2006 Contact name JOHN ARNOLD Telephone number +1 345 946 8002 If a connected EFM, name of NAofferee/offeror with which connected If a connected EFM, state nature of connection (Note 10) NA Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th Jan 20105:40 pmRNSHolding(s) in Company
18th Jan 20105:23 pmRNSHolding(s) in Company
13th Jan 20106:17 pmRNSHolding(s) in Company
12th Jan 20105:58 pmRNSHolding(s) in Company
6th Jan 20105:22 pmRNSHolding(s) in Company
5th Jan 20106:11 pmRNSHolding(s) in Company
4th Jan 201011:23 amRNSDirectorate Change
22nd Dec 20094:56 pmRNSShare Purchase Plan
1st Dec 200910:57 amRNSShare Purchase Plan
18th Nov 20097:00 amRNSBoard Change
12th Nov 20097:00 amRNSInterim Management Statement
3rd Nov 20095:13 pmRNSShare Purchase Plan
2nd Nov 200910:07 amRNSFlutiform EU Clinical Trial Successfully Completed
1st Oct 20091:21 pmRNSShare Purchase Plan
8th Sep 20092:09 pmRNSHolding(s) in Company
1st Sep 200910:09 amRNSShare Purchase Plan
1st Sep 20097:00 amRNSResearch Update
21st Aug 20097:00 amRNSHalf Yearly Report
3rd Aug 20092:13 pmRNSShare Purchase Plan
24th Jul 20093:56 pmRNSHolding(s) in Company
24th Jul 200911:01 amRNSHolding(s) in Company
20th Jul 200911:48 amRNSHolding(s) in Company
17th Jul 20097:00 amRNSRe Agreement
14th Jul 200911:08 amRNSHolding(s) in Company
10th Jul 20095:10 pmRNSHolding(s) in Company
9th Jul 20095:35 pmRNSHolding(s) in Company
1st Jul 20093:57 pmRNSDirector Declaration
30th Jun 20093:42 pmRNSShare Purchase Plan
30th Jun 200911:35 amRNSTotal Voting Rights
26th Jun 20096:09 pmRNSHolding(s) in Company
24th Jun 20094:59 pmRNSHolding(s) in Company
23rd Jun 20093:42 pmRNSHolding(s) in Company
22nd Jun 20094:15 pmRNSHolding(s) in Company
22nd Jun 20093:23 pmRNSConversion of Bonds
17th Jun 20095:43 pmRNSHolding(s) in Company
17th Jun 20094:44 pmRNSHolding(s) in Company
11th Jun 20095:09 pmRNSHolding(s) in Company
10th Jun 20095:30 pmRNSHolding(s) in Company
9th Jun 20095:18 pmRNSHolding(s) in Company
9th Jun 20093:00 pmRNSResearch Update
5th Jun 20096:16 pmRNSHolding(s) in Company
5th Jun 20095:15 pmRNSHolding(s) in Company
5th Jun 200910:36 amRNSHolding(s) in Company
4th Jun 20096:26 pmRNSHolding(s) in Company
3rd Jun 20094:46 pmRNSDirector/PDMR Shareholding
29th May 20096:20 pmRNSShare Purchase Plan
29th May 200911:37 amRNSTotal Voting Rights
28th May 20093:34 pmRNSHolding(s) in Company
27th May 20091:55 pmRNSReplacement: Conversion of ?50,000 6% 2024 Bonds
22nd May 20097:00 amRNSFlutiform NDA Accepted for Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.